Proton Pump Inhibitors for Obesity
(LiverLabPPI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.
Who Is on the Research Team?
Kathryn Kyler, MD, MS
Principal Investigator
Children's Mercy Hospital Kansas City
Are You a Good Fit for This Trial?
This trial is for children and young adults aged 6-21 with a BMI in the healthy range or higher, who may be generally healthy or have conditions like GERD, NAFLD, chronic abdominal pain, or obesity. Participants can currently be taking pantoprazole or lansoprazole. Those over 500lbs, with significant liver/renal impairment, pregnant/breastfeeding females, individuals with certain infections (hepatitis B/C/HIV), and those unable to undergo MRI due to metal implants are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are evaluated for the effect of liver fat on the pharmacology of PPIs and midazolam, if applicable
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pantoprazole
Pantoprazole is already approved in United States, European Union, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Mercy Hospital Kansas City
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator